CORDIS
EU research results

CORDIS

English EN
HEPATIC MICROFLUIDIC BIOREACTOR

HEPATIC MICROFLUIDIC BIOREACTOR

Objective

The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three cell types to induce and maintain their functional, differentiated state, and (b) optimisation of the matrix, oxygenation conditions, nutrient transport and physiological shear forces. The objectives are (1) to engineer the cellular components incorporated in the bioreactor to enable specific and spatially defined enrichment of the different cells from iPSC progeny, and, by gene editing, to allow non-invasive monitoring of the cellular state (differentiation and damage). (2) Aside from the molecular sensors, an array of electro-chemical sensors will be embedded in the reactors to assess liver-specific function and cellular health under repeated dose toxicity conditions, dynamically and in a high-throughput way. Cells and sensors will be built into (3) bioreactors that will be sequentially upgraded from 2D to 3D microfluidic reactors to ultimately allow full maintenance of mature functional hepatocytes, HSC and HSEC for >28 days. (4) As the ultimate goal is to use the device as a human-based alternative to rodent long-term hepatotoxicity studies, it will be of utmost importance to provide proof of concept that the 3D-devices reveal the hepatotoxicity of prototypical hepatotoxic compounds in vivo (5). “-Omics” and cell functionality studies will provide evidence that liver-like cells are present, exposed and affected by the selected toxic compounds. These ambitious objectives will be achieved by the excellent project team, composed of academic/industrial partners with unique and complementary biology, physiology, toxicology and technical skills from 7 EU Member States.

Coordinator

KATHOLIEKE UNIVERSITEIT LEUVEN

Address

Oude Markt 13
3000 Leuven

Belgium

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 788 019,20

Administrative Contact

Elke Lammertyn (Dr.)

Participants (12)

Sort alphabetically

Sort by EU Contribution

Expand all

VRIJE UNIVERSITEIT BRUSSEL

Belgium

EU Contribution

€ 585 899,65

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 279 561,31

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 276 801,80

THE HEBREW UNIVERSITY OF JERUSALEM

Israel

EU Contribution

€ 480 144,40

INTERUNIVERSITAIR MICRO-ELECTRONICA CENTRUM

Belgium

EU Contribution

€ 283 237,65

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 471 533,61

CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICROTECHNIQUE SA - RECHERCHE ET DEVELOPPEMENT

Switzerland

EU Contribution

€ 282 953,63

MEDICYTE GMBH

Germany

EU Contribution

€ 279 578,83

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 87 768,62

UNIVERSITETET I TROMSOE - NORGES ARKTISKE UNIVERSITET

Norway

EU Contribution

€ 281 749,57

INSERM TRANSFERT SA

France

EU Contribution

€ 413 878,35

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 188 873,38

Project information

Grant agreement ID: 266777

Status

Closed project

  • Start date

    1 January 2011

  • End date

    31 December 2015

Funded under:

FP7-HEALTH

  • Overall budget:

    € 9 400 000

  • EU contribution

    € 4 700 000

Coordinated by:

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

This project is featured in...